Smart cancer nanomedicine

Roy van der Meel, Einar Sulheim, Yang Shi, Fabian Kiessling, Willem J.M. Mulder, Twan Lammers*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

767 Citations (Scopus)
2 Downloads (Pure)


Nanomedicines are extensively employed in cancer therapy. We here propose four strategic directions to improve nanomedicine translation and exploitation. (1) Patient stratification has become common practice in oncology drug development. Accordingly, probes and protocols for patient stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclusion in clinical trials. (2) Rational drug selection is crucial for clinical and commercial success. Opportunistic choices based on drug availability should be replaced by investments in modular (pro)drug and nanocarrier design. (3) Combination therapies are the mainstay of clinical cancer care. Nanomedicines synergize with pharmacological and physical co-treatments, and should be increasingly integrated in multimodal combination therapy regimens. (4) Immunotherapy is revolutionizing the treatment of cancer. Nanomedicines can modulate the behaviour of myeloid and lymphoid cells, thereby empowering anticancer immunity and immunotherapy efficacy. Alone and especially together, these four directions will fuel and foster the development of successful cancer nanomedicine therapies.

Original languageEnglish
Pages (from-to)1007-1017
Number of pages11
JournalNature nanotechnology
Issue number11
Publication statusPublished - 1 Nov 2019


  • n/a OA procedure


Dive into the research topics of 'Smart cancer nanomedicine'. Together they form a unique fingerprint.

Cite this